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Abstract 
A novel stability-indicating RP-HPLC assay method was developed and 
validated for quantitative determination of rebamipide in bulk and tablet dosage 
form. Rebamipide (drug and drug product) solutions were exposed to acid and 
alkali hydrolysis, thermal stress, oxidation by hydrogen peroxide and photo-
degradation. Experimental design has been used during forced degradation to 
determine significant factors responsible for degradation and to obtain optimal 
degradation conditions. In addition, acid and alkali hydrolysis was performed 
using a microwave oven. The chromatographic method employed the HiQ sil 
C-18HS (250 × 4.6 mm; 5 µm) column with mobile phase consisting of 0.02 M 
potassium phosphate (pH adjusted to 6.8) and methanol (40:60, v/v) and the 
detection was performed at 230 nm. The procedure was validated for specificity, 
linearity, accuracy, precision and robustness. There was no interference 
observed of excipients and degradation products in the determination of the 
active pharmaceutical ingredient. The method showed good accuracy and 
precision (intra and inter day) and the response was linear in a range from 0.5 
to 5 µg mL
−1. The method was found to be simple and fast with less trial and 
error experimentation by making use of experimental design. Also, it proved that 
microwave energy can be used to expedite hydrolysis of rebamipide.  86  S. Sonawane and P. Gide:   
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Introduction  
Forced degradation is an integral part of drug development process. Although most of the 
literature defines the concept of forced degradation they do not provide detailed 
information about a forced degradation strategy [1,  2]. The experimental conditions to 
conduct forced degradation are described in a general way [3,  4] but exact stress 
conditions to be applied are not described.  
Generally, a trial and error approach is adopted to select the strength, temperature and 
time of exposure to achieve degradation to an extent of 10–20% [5]. Such trial and error 
approach is cost, time and labor intensive and should be substituted by more systematic 
approaches. Also, if the experiments are performed randomly the results obtained will also 
be random. Therefore, it is necessary to plan the experiments in such a way that the real 
experimental situation as well as the theoretical background of experiments is obtained.  
Factorial design is a type of experimental design in which all the possible combinations of 
factors and levels are investigated [6, 7]. Also, it has been observed that the conventional 
method of heating the drug in presence of water, acid or alkali using a heating mantle or 
water bath can prove to be time consuming and a comparatively slow process, ich can be 
substituted by use of microwave energy. The conventional method of heating uses an 
external source, in which the heat transfer depends upon the thermal conductivity of 
various materials. This heat initially leads to the increase in the temperature of the reaction 
vessel and thereafter, of the reaction mixture. By contrast, microwave energy produces 
efficient internal heating by direct coupling of microwave energy with polar molecules. 
Microwave assisted reactions are mainly based on the efficient heating of materials by 
microwave dielectric heating effects. Microwave dielectric heating depends on the ability of 
a specific material to absorb microwave energy and convert it into heat. Hence it is less 
time consuming [8].  
Chemically, Rebamipide is N-[(4-chlorophenyl)carbonyl]-3-(2-oxo-1,2-dihydroquinolin-
4-yl)alanine (Fig. 1) [9]. 
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Fig. 1.  Chemical Structure of Rebamipide  
It is a fine white to off-white powder that is soluble in dimethyl formamide, sparingly soluble 
in methanol, water, ethyl acetate and acetonitrile, and practically insoluble in n–hexane. It   Optimization of Forced Degradation Using Experimental Design and Development of a …  87 
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is an antiulcer agent used for mucosal protection, healing of gastro duodenal ulcers and in 
the treatment of gastritis [10]. It is also used for the treatment of Behcet’s disease [11]. 
Rebamipide is known to be rapidly absorbed following oral application (typical dose is 
100 mg).  
Literature survey revealed very few quantitative analytical methods for estimation of 
rebamipide with bioanalytical applications [12–15]. Till date no stability-indicating HPLC 
method has been reported for quantification of rebamipide 
The ICH guidelines require performing forced degradation of drug substance, which can 
help to indentify the likely degradation products and can be useful to establish degradation 
pathways and validate a stability-indicating method. Moreover, the validated stability-
indicating method should be applied to the stability-study. Thus, the aim of this study was 
to develop and validate stability-indicating LC method for quantification of rebamipide in 
bulk and tablets according to official codes. Also, an attempt was made to simplify forced 
degradation studies by adopting experimental design and microwave energy to expedite 
hydrolysis.  
Materials and Methods  
Drug and Chemicals 
Pharmaceutical grade rebamipide was procured as gift sample from Macleods 
Pharmaceuticals Ltd., Mumbai (India), certified to contain 99.96 % and used without 
further purification. Methanol and water used in analysis were of HPLC grade. Potassium 
dihydrogen phosphate, dipotassium hydrogen phosphate, hydrochloric acid, sodium 
hydroxide, hydrogen peroxide used were of analytical grades. All chemicals were 
purchased from SD Fine Chemicals, Mumbai (India). The 0.45 μ Nylon filter papers were 
purchased from Pall India Pvt. Ltd, Mumbai (India).  
Equipments: 
HPLC system used consisted of pump PU – 2080 plus (JASCO, Japan) with Rheodyne 
loop injector (7725i) of capacity 20 μL. Detection was carried out by UV – 2075 detector 
(JASCO, Japan). The data acquisition was done using Borwin chromatography software 
version 1.50.  
Acid and alkali induced forced degradation was carried out using Catalyst Scientific 
Microwave Oven System (Model: CATA 2R, Range: 140-700 W, Make: Catalyst System, 
Pune, India). 
Chromatographic Conditions  
The chromatographic separation was performed in an HiQ sil C-18HS column (250 × 4.6 
mm I. D., 5 µm, Kya Technologies Corporation, JAPAN). The mobile phase comprising a 
mixture of 0.02 M potassium phosphate (pH adjusted to 6.8) and methanol (40:60, v/v) at a 
flow-rate of 1.0 mL. min
−1 with iscocratic elution. The injection volume was 20 µL for both 
reference substance and drug product solutions and the run time was 7 min. Detection 
was carried out at 230 nm. 88  S. Sonawane and P. Gide:   
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Experimental 
Forced Degradation Study 
Generation of Forced Degradation Samples  
The forced degradation study was conducted on rebamipide in both bulk and tablets as 
well as on placebo (excipients excluding drug). Tablets containing 100 mg of rebamipide, 
were prepared in-house.  
All stress studies were performed at an initial drug concentration of 1 mg.mL
−1. Solutions 
of rebamipide tablets in each medium were prepared by weighing an amount of finely 
powdered tablets equivalent to an amount 100 mg of rebamipide. The solubilization of the 
drug from tablet powder in each medium was effected by sonicating it for 10 min followed 
by filtration and the final volume was adjusted with methanol.  
Acidic and alkaline hydrolysis were performed by using microwave oven with full factorial 
optimization procedure. On the basis of preliminary experiments three independent 
factors; strength of acid/alkali (Normality), irradiation time (min) and microwave power 
(Watt) were chosen as input and % degradation as output. Similarly, to perform 
degradation under wet heat conditions using microwave oven, two factors were 
considered; irradiation time (min) and microwave power (Watt) as input and % degradation 
as output.  
The high level of each factor was considered as "+1" and low level as "−1".  
Oxidative studies were carried out at room temperature in 30 % hydrogen peroxide for 24h 
then heated on water bath for 10 min to remove excess of hydrogen peroxide.  
At the end of exposure, the samples from each hydrolyzed and oxidized drug solutions 
were diluted to 100 mL with methanol. The flasks were thoroughly covered with aluminium 
foil, labeled appropriately and stored in refrigerator till analysis. 
The photodegradation study was performed by exposing the drug powder, spread as a thin 
film in a covered petri plates and exposed to direct sunlight for 48 h. Similarly, tablets of 
rebamipide was taken in petri plates and exposed to direct sunlight for 48 h. A control 
study in dark was also run simultaneously.  
For the dry heat study, the drug powder and tablets of rebamipide were taken in separate 
petri plates and kept in oven at 80 °C for 48 h.  
Solutions of photodegraded and dry heat condition samples of drug powder were prepared 
by dissolving 100 mg of sample in sufficient methanol to produce 100 mL. While, from 
photodegraded tablets and tablets exposed to dry heat in an oven; powder equivalent to 
100 mg of rebamipide was weighed and dissolved in sufficient methanol, sonicated for 10 
min, filtered and volume was made to 100 mL with methanol. Finally, each sample solution 
was diluted with mobile phase to get final concentration of 10 μg mL
−1 and subjected to 
chromatographic analysis. In each case, suitable blanks and controls were used to 
preclude errors.  
   Optimization of Forced Degradation Using Experimental Design and Development of a …  89 
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Method Validation 
Validation was performed with respect to ICH guideline Q2 (R1) [16]. To establish linearity 
and range; standard stock solution containing 1mg mL
−1 of rebamipide in methanol was 
diluted with mobile phase to get solutions in the concentration range of 0.5–5 µg mL
−1. The 
calibration curve standards were analyzed in triplicate and the peak area was plotted 
against corresponding drug concentration and subjected to least square linear regression 
to get an equation for best fit line.  
To perform formulation assay; 20 tablets were weighed and finely powdered. A quantity of 
powder equivalent to 100 mg of rebamipide was transferred to 100 mL volumetric flask 
and sonicated with 70 mL methanol for 10 min, filtered and volume was made up to the 
mark with methanol. Similarly, the placebo stock solution was prepared. Suitable dilutions 
were made with mobile phase and subjected to chromatographic analysis.  
The accuracy and precision were determined by fortifying a placebo with 80 mg, 100 mg 
and 120 mg of rebamipide (80 %, 100 % and 120 % of the label claimed, respectively) 
diluted suitably with mobile phase. The resulting mixtures were analyzed in triplicates over 
three days. The % recovery of added drug and % RSD were taken as a measure of 
accuracy and precision, respectively. Also, the results obtained were subjected to one way 
ANOVA and within-day mean square and between-day mean square was determined and 
compared using F-test.  
For the determination of specificity, a placebo mixture was subjected to chromatographic 
analysis before and after applying stress conditions. Absence of peaks in the blank runs at 
the retention time of drug was taken as indication of specificity.  
Tab. 1.  Experimental matrix and their resulting % degradation in microwave assisted 
alkali hydrolysis 
Expt  No. X1 X2 X3 Degradation  (%) 
1 0.1  15  420  0 
2 1  15  420  0 
3 0.1  30  420  2 
4 1  30  420  8 
5 0.1  15  700  17 
6 1  15  700  21 
7 0.1  30  700  28 
8 1  30  700  33 
X1: Concentration of NaOH (N), X2: irradiation time (min), 
X3: Microwave power (Watt) 
 
Results and Discussion 
From the preliminary experiments no degradation was found under acid and water 
hydrolysis using microwave oven as well as with conventional method of heating. Hence, it 
was decided not to proceed further with these conditions. But for alkali hydrolysis with 
microwave oven as well as under conventional method of heating, degradation has been 90  S. Sonawane and P. Gide:   
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obtained. Hence, it was decided to apply an experimental design for it to get an optimum 
degradation conditions.  
Three independent factors (concentration of alkali, irradiation time and microwave power) 
were studied at two levels (−1 and +1) i.e. 2
3 factorial design. Hence, 8 experiments were 
performed. The experimental matrix and resulting % degradation are presented in Table 1.  
From the Table 1, the relationship obtained between input and output was evaluated by 
using multiple regression equation;  
 Y  =  β0 + β1X1 + β2X2 + β3X3 + β12X1X2 + β13X1X3 + B23X2X3 + β123X1X2X3  
where, Y is the output (% degradation), β0 is the intercept, β1, β2, β3, β12, β23, β13 and 
β123 represents regression coefficients and X1, X2 and X3 as independent variables.  
The values of regression coefficient (βi) for multiple regression equation were calculated 
as;  
  n
Xi
i β
2
∑ =
 
where, Xi is the value of column (X1, X2 or X3) and Y is the % degradation obtained. From 
the coefficient obtained the multiple regression equation for alkaline degradation was 
obtained as;  
Eq. 1.  Y = 13.62 + 1.88 X1 + 4.12 X2 + 11.12 X3 + 0.88 X1X2 + 1.62 X2X3 +  
0.38 X1X3 − 0.62 X1X2X3 
Further, to determine the significant factors with respect to Y (% degradation); Yates 
analysis was performed and the F values were determined. It has been found that the 
F-value for irradiation time and in combination with microwave power has significant effect 
on % degradation of rebamipide. Therefore, the use of these factors for determination of % 
degradation in the optimization design was justified.  
Also, the magnitude of corresponding coefficients in multiple regression equation shows 
their significant effect on each factor. Thus, from the Eq. 1, it has been observed that 
factor X3 (microwave power) has more significant effect on % degradation of rebamipide 
than factor X2 (irradiation time) and factor X1 (concentration of NaOH).  
Thus, by substituting X1 = 0 in Eq. 1; the new equation obtained is;  
Eq. 2.  Y = 13.62 + 4.12 X2 + 11.12 X3 + 1.62 X2X3 
By rearranging the Eq.2,  
 
X2   1.62     X1   11.12
X2   4.12     13.62   Y 
3
+
− −
= X     Optimization of Forced Degradation Using Experimental Design and Development of a …  91 
Sci Pharm. 2011; 79: 85–96 
Further, the values of Y (% degradation) were assumed to be 5, 10 and 15 %. Thus, the 
values for X3 at various levels of X2 such as X2 = −1, −0.75, −0.5, −0.25, 0, 0.25, 0.5, 
0.75 and 1 were calculated and contour plot was plotted as shown in Fig2.  
 
Fig. 2.  Contour Plot for Alkali degradation  
To get actual values for three factors, the coded values were decoded as follows;  
 
leves   the   of   difference   the   half –  one
levels   two   of   average   the – X
     Value d Transforme =  
Actual experiments were performed in triplicates. The average of three experiments was 
compared with the predicted experiment. There was no significant difference observed 
between predicted and experimental values. The optimized experimental conditions in 
comparison to predicted experiment are depicted in Table 2.  
Tab. 2.  Optimized Experiment with comparison of Predicted and Observed results of 
alkaline condition  
X1 
(Concentration 
of NaOH) 
X2 
(irradiation 
Time) 
X3 
(Microwave 
Power) 
Predicted 
Degradation
Obtained 
Degradation* 
0.55 N  6.7 min  525 W  10%  8.74 ± 0.38 % 
* Mean of three experiments ± SD 
 
Further, when drug was refluxed for 1 h with 0.5 N NaOH using heating mantle; around 8 
% degradation was obtained. The time consumption for this was very high as compared to 
heating using microwave oven. Thus, it was proved that microwave energy can be used to 
expedite forced degradation of rebamipide under alkaline conditions.  92  S. Sonawane and P. Gide:   
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Development of Method 
To get an adequate retention of rebamipide, initially, different mobile phases were tried in 
isocratic mode with a flow rate of 1 mL min
−1. All the buffer solutions were prepared as per 
the procedure described by Snyder et al. [17]. Initially, acetonitrile: water (70: 30 %, v/v) 
mobile phase was tried. The retention time of rebamipide was 3.8 min. Further, 
acetonitrile: potassium phosphate buffer (pH 3, 0.02 M) (35: 65 %, v/v) was tried which 
gave a retention of 7.25 min. The same mobile phase was tried on the forced degradation 
samples, but rebamipide was found to be poorly resolved from its degradation products. 
Hence, it was decided to select the mobile phase which gives good resolution of 
rebamipide from its degradation products. The approximate similar type of result was 
obtained when acetate buffer was replaced with phosphate buffer. Now further, it was 
decided to increase the pH of the mobile phase. It has been found that mobile phase 
consisting of pH 6.8 buffers showed better resolution of the drug from its degradation 
products than those consisting of pH 3 buffers. Since the phosphate buffer has a better 
buffer capacity compared to acetate buffer, it was decided to select it as aqueous phase 
and methanol as organic phase. Hence, the mobile phase consisting of methanol: 0.02 M 
phosphate buffer (pH adjusted to 6.8) with the ratio of 60:40 % v/v was selected as the 
optimum mobile phase which gave good resolution of rebamipide from its degradation 
products along with good peak shape and lesser retention time. The maximum absorption 
wavelength of reference drug and forced degradation samples was found to be 230 nm 
and hence selected as detection wavelength for analysis.  
The average retention time was found to be 5.7 min. For alkaline stressed sample two 
degradation products were obtained one at 2.8 min (Deg 1) and another at 4.0 min 
(Deg 2), respectively. The chromatograms of unstressed rebamipide and alkali stressed 
samples of rebamipide are shown in Fig. 3.  
 
Fig. 3.  Chromatograms obtained from (A) Reference substance, (B) microwave 
assisted alkaline degradation  
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Method Validation 
The data obtained in the calibration experiments when subjected to linear regression 
analysis showed a linear relationship between peak areas and concentrations in the range 
of 0.5–5 µg mL
−1 (equation: Y = 601211X + 41127). When the tablets were analyzed using 
the developed method, the results obtained were in good agreement with the nominal 
amount of the drug. The drug content was found to be 101.39 ± 1.37 (n=3).  
The data obtained from accuracy and precision experiments are summarized in Table 3.  
Tab. 3.  Accuracy and Precision Studies  
Amount 
added (mg) 
Amount found (mg)  Within 
mean 
square 
Between 
mean 
square 
F 
  Days      
  1 2 3      
 78.34  79.24  80.39       
80  79.43 81.09 80.43  1.64  1.72 1.05 
 81.33  80.11  82.72       
Mean 79.70  80.14  81.18      
% R. S. D.  1.89  1.15  1.64      
 101.69  98.75  99.85      
100  99.68 97.83  102.79  2.79  6.79 2.43 
 100.72  101.06  104.03       
Mean  100.69 99.21 102.22      
% R. S. D.  0.99  1.67  2.10      
 118.11  120.16  119.86       
120  120.36 119.88 120.43  2.34  3.82  1.63 
 119.62  117.44  123.34       
Mean 119.36  119.16  121.21      
% R. S. D.  0.96  1.25  1.53      
 
The mean values of amount estimated of the drug were found very close to amount added 
and % RSD values of intra-day were found very low indicating acceptable accuracy and 
precision of the method. The intra and inter-day results at each level were subjected to 
one way ANOVA and F values at each level were obtained as a ratio of Between Mean 
Square to the Within Mean Square (F = BMS/WMS). The obtained values were found to 
be less than the tabulated F (2, 6) at α = 0.05 (Tabulated F value = 5.14). These indicated 
that there was no significant difference between intra and inter-day variability, suggesting 
good intermediate precision of the method.  
The chromatograms of blank and placebo solutions showed no interfering peak at the 
retention time of the drug indicating specificity of the developed method.  
The method comply with system suitability each time in accordance to theoretical plates 
(more than 5000), tailing (below 2) and % RSD of the drug concentration in reference 
standard (n = 3) and test (n = 5) (below 2).  94  S. Sonawane and P. Gide:   
Sci Pharm. 2011; 79: 85–96 
There was no significant change in retention time of rebamipide and its degradation 
products after introducing small changes in the mobile phase composition indicated 
robustness of the method. 
Forced degradation Behavior 
The similar degradation behavior of the drug in bulk and tablets indicted that there was no 
interaction between the drug and excipients. The drug was found to be stable to acid 
hydrolysis, oxidative, wet heat conditions and photolytic conditions; as no decrease in 
peak area of drug was observed with no secondary peaks. The alkaline hydrolysis leads to 
breakdown of amide (C–N) bond which leads to the formation of two degradation products; 
p-chlorobenzoic acid (I) and 3-(2-oxo-1,2-dihydroquinolin-4-yl)alanine (II). When standard 
p-chlorobenzoic acid was chromatographed with same chromatographic conditions; it has 
been observed that retention time of Deg 2 matched with retention time of standard p-
chloro benzoic acid (4.06 min for Deg 2 and 4.12 min for standard p-chlorobenzoic acid). 
Hence, it has been confirmed that one of the degradation product was p-chlorobenzoic 
acid (Deg 2) and another might be 3-(2-oxo-1,2-dihydroquinolin-4-yl)alanine (Deg 1) as 
shown in Fig. 4.  
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Fig. 4. Proposed alkaline degradation pathway of rebamipide 
Conclusion 
A LC method was developed and validated statistically for quantitative determination of 
rebamipide. By making the use of full factorial experimental design real experimental 
situation was obtained which helped to reduce the trial and error experimentation. With 
Yate’s analysis the factor or combination of the factors which are most likely to effects   Optimization of Forced Degradation Using Experimental Design and Development of a …  95 
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degradation were identified. The comparison of conventional degradation using reflux and 
microwave assisted degradation proved that microwave energy can be utilized to expedite 
forced degradation for hydrolytic conditions. Validation experiments evidenced that the LC 
analytical method is linear in the proposed working range, as well as accurate, precise, 
specific and capable of separating the main drug from its degradation products. Due to 
these characteristics, the method is stability-indicating and may be applicable to routine 
analysis of rebamipide in tablets because there is no official method available.  
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